И. Г. Гордеев
A5003107578- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Biosimilars and Bioanalytical Methods
- Diabetes Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- SARS-CoV-2 and COVID-19 Research
- Healthcare Systems and Public Health
- Diabetes Management and Research
- Hormonal Regulation and Hypertension
- COVID-19 Impact on Reproduction
- Intensive Care Unit Cognitive Disorders
- Diet and metabolism studies
- Adipokines, Inflammation, and Metabolic Diseases
- Monoclonal and Polyclonal Antibodies Research
- Heart Failure Treatment and Management
- Respiratory Support and Mechanisms
- Cardiac, Anesthesia and Surgical Outcomes
City Clinical Hospital No15 named. O. M. Filatova
2017-2024
Pirogov Russian National Research Medical University
2012-2024
City Clinical Hospital
2019-2024
Ministry of Health of the Russian Federation
2018-2022
Technical University of Munich
2019
Bridgepoint (United Kingdom)
2013
Scientific Research Institute of Healthcare Organization and Medical Management
2011
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for treatment COVID-19 patients. pilot stage Phase II/III clinical trial, enabled SARS-CoV-2 viral clearance in 62.5% patients within 4 days, and was safe well-tolerated. Clinical Trials Registration. NCT04434248.
Effective treatments for patients with severe COVID-19 are needed.To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in hospitalized COVID-19.This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals Europe and United States. A total 454 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), systemic hyperinflammation defined by increased blood concentrations C-reactive protein or ferritin were enrolled between...
Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role combination other treatments is uncertain. Here we evaluated whether plus remdesivir provides greater benefit than alone pneumonia. This randomized, double-blind, placebo-controlled, multicenter trial included hospitalized requiring > 6 L/min supplemental oxygen. Patients were randomly assigned (2:1 ratio) to receive 8 mg/kg or placebo intravenously ≤ 10 days remdesivir. The primary...
Abstract Objective and design The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy safety IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. Subjects study included 217 patients. eligible were men non-pregnant women aged 18 years or older, hospitalized for COVID-19 pneumonia. Treatment 206 randomized (1:1) receive single subcutaneous administration LVL 324 mg placebo, both combination standard care (SOC). 204...
The article presents the results of three-year use netakimab (NTK) in patients with ankylosing spondylitis (AS) as part phase III BCD-085-5/ASTERA study. Objective : to evaluate long-term efficacy and safety NTK over a period active AS. Material methods . – double-blind, multicenter, randomized clinical trial that enrolled AS (BASDAI ≥4) back pain intensity ≥4 on numeric rating scale inefficacy or intolerance non-steroidal anti-inflammatory drugs biologic drugs. A total 228 were 1:1 ratio...
ABSTRACT In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for treatment COVID-19 patients. pilot stage Phase II/III clinical trial, enabled SARS-CoV-2 viral clearance in 62.5% patients within 4 days, and was safe well-tolerated.
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A. Objective . The main objective of BCD-085-5/ASTERA study was to prove superiority NTK over placebo and assess its’ safety in patients with active AS. Subjects methods double-blind, multicenter, randomized, placebo-controlled, phase III study, which included 228 adult AS, persisting despite treatment NSAIDs. AS considered at BASDAI score ≥ 4.0. Patients were blindly randomized (1:1) receive subcutaneous injections...
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives data obtained during 52-week follow-up of AS patients in phase III ASTERA study. Objective : study efficacy safety NTK when used long with active AS. Patients methods . investigation enrolled 228 AS, whom nonsteroidal anti-inflammatory drugs or biological agents were ineffective....
Trimodulin (human polyvalent immunoglobulin [Ig] M ~ 23%, IgA 21%, IgG 56% preparation) has previously been associated with a lower mortality rate in subpopulation of patients severe community-acquired pneumonia on invasive mechanical ventilation (IMV) and clear signs inflammation. The hypothesis for the ESsCOVID trial was that trimodulin may prevent inflammation-driven progression coronavirus disease 2019 (COVID-19) to critical or even death. Adults COVID-19 were randomised receive...
In opinion the Expert council provides management tactics for patients with hypertriglyceridemia (HTG). It is demonstrated that HTG a common condition in overweight and an important component of residual risk. creates additional conditions progression atherosclerosis, so level triglycerides (TG) recommended to be measured high, very high extremely risk level. An indication appointment drugs reduce concentration TG its more than 2,3 mmol/L. Statins are agents choice cardiovascular disease...
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD20 (BCD-020, Acellbia®) that is biosimilar of rituximab (RTM; MabThera®, F. Hoffmann-La Roche Ltd., Switzerland). In recent years, there been evidence RTM can be used at lower doses than those given in the standard recommendations and instructions for use this drug. This serves as basis BCD-020-4/ALTERRA (ALTErnative Rituximab regimen Rheumatoid Arthritis) trial, objective which was to...
The article contains the data obtained during 156-week follow-up of patients with ankylosing spondylitis (AS) in ASTERA phase III study. Objective : to evaluate effect impact netakimab (NTK) on quality life (QoL), back pain and work capacity active AS. Material methods . study enrolled 228 AS who were randomized 1:1 receive NTK 120 mg or placebo. At week 52, Group 1 achieved ASAS20 continued therapy (NTK at a dose once every 2 weeks) until 156. Patients (placebo/NTK) received drug...
Aim. Life quality is an integral parameter of medical care efficacy. In incomplete revascularization after myocardial infarction the life might change in relevance with severity residual lesion. The study done aim to reveal specifics patients such clinical situation. Material and methods. investigation 100 (mean age 63±0,9 y.o.) acute ST-elevation revascularization, those 20 underwent delayed surgery (percutaneous or bypass) — group 1; 54 had no further (group 2); 26 did not have primary 3....
This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety BCD-055 innovator (IFX) in patients with ankylosing spondylitis (AS). Objective : The purpose phase I study ASART-1 was to evaluate pharmacokinetic profile prove its equivalence Remicade®, III ASART-2 conducted tolerability comparison Remicade® active AS. Patients methods Both studies were as international multi-center...
Aim. To investigate on the clinical, anamnestic and laboratory-instrumental predictors of short term outcomes development in pulmonary thromboembolism (PTE). Material methods. study, 136 patients included with high intermediate risk PTE confirmed by multispiral computed tomography. The endpoints were obstructive shock, fatal relapse, outcome, necessity resuscitation, urgent thrombolysis hemodynamic support. Follow-up lasted for 30 days. Patients selected to groups complicated (n=44)...
Научно-практическая ревматология.2019;57(6):668-677 О р и г н а л ь ы е с д о в я 1 ФГБНУ «Научно-исследовательский институт ревматологии им.В.А.Насоновой», Москва, Россия; 2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им.И.И.Мечникова» Минздрава России, Санкт-Петербург, 3 «Казанский университет» Казань, 4 ГАУЗ НСО «Городская клиническая поликлиника №1», Новосибирск, 5 НУЗ «Отделенческая больница на станции Смоленск ОАО «РЖД», Смоленск, 6 ГБУЗ НО «Нижегородская...
The article focuses on the comparative analysis of tactics rational complete and incomplete revascularizations in patients with ST elevation myocardial infarction angina, underwent multivessel stenting coronary bypass grafting. Patients diffuse atherosclerotic lesion arteries are one most strenuous kinds patients. demand for revascularization high this group and, by data several authors, is up to 70% among all surgeries. This origins from changes demographics (population ageing) as manifest...
Introduction: A number of studies uses severity lung damage as a predictor changes in the long-term period. Objective: To evaluate computed tomography (CT) findings period after extremely severe (CT-4) caused by COVID-19 during different pandemic waves and compare those with clinical data. Materials methods: The study included 51 patients (51.0% them were women; age, 57 ± 12 years [95% CI, 53-60]) that treated for O.M. Filatov City Clinical Hospital No. 15 (Moscow, Russian Federation) gave...
The paper gives data on the clinical efficiency and safety profile of long-term use infliximab (INF) biosimilar BCD-055 versus reference drug Remicade® (REM) in a population patients with active ankylosing spondylitis (AS). Subjects methods . An international multicenter randomized double-blind Phase III trial was conducted 199 who were into two groups 2:1 ratio received or REM at dose 5 mg/kg 0, 2, 6 weeks, then every 8 weeks. Efficiency assessment made 14, 30 54 weeks least one INF...
<h3>Background</h3> Efficacy and safety of netakimab (NTK), a humanized anti-IL17A antibody, was established in phase 2 clinical trials patients (pts) with radiographic axial spondyloarthritis (r-axSpA)<sup>1</sup> psoriasis<sup>2</sup>. <h3>Objectives</h3> The abstract presents 16-week data from ongoing ASTERA study (NCT03447704) pts active r-axSpA. <h3>Methods</h3> is 3 international double-blind placebo (PBO)-controlled study. 228 adult r-axSpA, (BASDAI ≥ 4) despite the standard NSAIDs,...